Sanofi Bioverativ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sanofi bioverativ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sanofi Bioverativ Today - Breaking & Trending Today

Edison Investment Research Limited: Oxford Biomedica (OXB): Driving Innovation in a Thriving CGT Industry


Edison Investment Research Limited: Oxford Biomedica (OXB): Driving Innovation in a Thriving CGT Industry
LONDON, UK / ACCESSWIRE / May 28, 2021 / Oxford Biomedica (OXB) is one of few global lentiviral vector manufacturers with capacity in a thriving cell and gene therapy industry, and its FY20 results highlight strong operational progress throughout the business. OXB boasts a diversified revenue base; and FY20 benefited from new deals including Juno/BMS covering multiple CAR-T programmes, as well as increased bioprocessing and commercial development activities for several customers including Novartis and the AZN COVID-19 vaccine. Post period, OXB upgraded its financial guidance for the COVID-19 vaccine supply agreement with AZN to in excess of £100m by end FY21. In the long term, much value resides in OXB s ability to develop and monetise its own CGT assets, which are progressing towards the clinic. Bolt on acquisitions that complement the pipeline or enhance technology capa ....

New York , United States , South Africa , New South Wales , City Of , United Kingdom , Noord Holland , Tel Aviv , Oxford Biomedica , Sanofi Bioverativ , John Priestner , Susie Jana , Edison Investment Research , Financial Conduct Authority , Financial Conduct , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , புதியது தெற்கு வேல்ஸ் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , நூற்த் ஹாலண்ட் , தொலைபேசி அவிவ் , ஆக்ஸ்ஃபர்ட் பயோமெடிகா , சூசி ஜன , எடிசன் முதலீடு ஆராய்ச்சி , நிதி நடத்தை அதிகாரம் ,

GBT In-Licenses Two Sickle Cell Small Molecule Programs from Sanofi


Share
Rare Daily Staff
Global Blood Therapeutics entered into an agreement with Sanofi to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease: one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress.
These mechanisms are distinct and potentially complementary to that of GBT’s Oxbryta, a novel hemoglobin S polymerization small molecule inhibitor approved in the United States for the treatment of Sickle Cell Disease in patients ages 12 years and older. The programs, from Sanofi’s Bioverativ subsidiary, supplement GBT’s existing pipeline and support the company’s strategy to address SCD from multiple approaches. ....

United States , Jung Choi , Sanofi Bioverativ , Blood Therapeutics , Sickle Cell Disease , South Asian , Southern European , Middle Eastern , ஒன்றுபட்டது மாநிலங்களில் , ஜங் சோய் , இரத்தம் சிகிச்சை , அரிவாள் செல் நோய் , தெற்கு ஆசிய , தெற்கு ஐரோப்பிய , நடுத்தர கிழக்கு ,